Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy
| Autor: | Sylvie Vézina, Stéphane Lavoie, Harold Dion, Réjean Thomas, Serge Gallant, Danielle Legault, N. Machouf, Benoit Trottier, Danièle Longpré, Vinh-Kim Nguyen, Michel Boissonnault |
|---|---|
| Přispěvatelé: | Anthropology of Health, Care and the Body (AISSR, FMG) |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents Fixed-dose combination HIV Infections Pharmacology Emtricitabine Abacavir Internal medicine medicine Humans Pharmacology (medical) Darunavir Retrospective Studies Sulfonamides Ritonavir business.industry Lamivudine Abacavir/Lamivudine Middle Aged Dideoxynucleosides CD4 Lymphocyte Count Regimen Drug Combinations Infectious Diseases Drug Therapy Combination Female business medicine.drug |
| Zdroj: | HIV Clinical Trials, 13(6), 335-342. Taylor and Francis Ltd. |
| ISSN: | 1528-4336 |
| Popis: | Background: Current treatment guidelines recommend the use of tenofovir (TDF) and emtricitabine (FTC) along with a third agent to treat HIV-positive adults. However, other treatment options, including the use of abacavir (ABC) and lamivudine (3TC) when used with ritonavir-boosted darunavir (DRV/r), have rarely been studied. Objective: We evaluated the safety and efficacy of the coformulation of ABC/3TC administered with DRV/r in treatment-naïve and treatment-experienced patients. Methods: HIV-infected adults who received an open-label combination of ABC/3TC/ DRV/r were followed in a community clinic in Montréal. Patients had no resistance to any of the compounds in their regimen. Viral load (VL), CD4 cell count, AST, ALT, and creatinine levels were examined throughout the 48 weeks of follow-up. Results: Sixty-seven patients with a mean age of 45 years were enrolled. Two did not return for follow-up and were excluded. Thirty-five (52%) were treatment- experienced and the remaining were treatment-naïve. HLA-B*5701 test results were available for 56 patients and none were positive. At baseline, mean VL was 4.8 log for treatment-naïve and 2.3 log for experienced patients. Twelve patients discontinued the study regimen prior to reaching the endpoint. At week 48, 79% had a VL |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|